Show simple item record

Absorption Rate Limit Considerations for Oral Phosphate Prodrugs

dc.contributor.authorForsberg, Markusen_US
dc.contributor.authorFleisher, Daviden_US
dc.contributor.authorLi, Lilian Y.en_US
dc.contributor.authorHeimbach, Tychoen_US
dc.contributor.authorFlynn, Gordon L.en_US
dc.contributor.authorMatsunaga, Yasushien_US
dc.contributor.authorOh, Doo-Manen_US
dc.contributor.authorSavolainen, Joukoen_US
dc.contributor.authorLeppänen, Jukkaen_US
dc.date.accessioned2006-09-08T19:19:26Z
dc.date.available2006-09-08T19:19:26Z
dc.date.issued2003-06en_US
dc.identifier.citationHeimbach, Tycho; Oh, Doo-Man; Li, Lilian Y.; Forsberg, Markus; Savolainen, Jouko; Leppänen, Jukka; Matsunaga, Yasushi; Flynn, Gordon; Fleisher, David; (2003). "Absorption Rate Limit Considerations for Oral Phosphate Prodrugs." Pharmaceutical Research 20(6): 848-856. <http://hdl.handle.net/2027.42/41498>en_US
dc.identifier.issn0724-8741en_US
dc.identifier.issn1573-904Xen_US
dc.identifier.urihttps://hdl.handle.net/2027.42/41498
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=12817887&dopt=citationen_US
dc.description.abstractPurpose . To evaluate the potential of phosphate ester prodrugs to significantly improve the absorptive flux of poorly soluble parent drugs.en_US
dc.format.extent191753 bytes
dc.format.extent3115 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherKluwer Academic Publishers-Plenum Publishers; Plenum Publishing Corporation ; Springer Science+Business Mediaen_US
dc.subject.otherBiomedicineen_US
dc.subject.otherMedical Lawen_US
dc.subject.otherPhosphate Ester Prodrugen_US
dc.subject.otherProtein Effectsen_US
dc.subject.otherAbsorptionen_US
dc.subject.otherBiomedical Engineeringen_US
dc.subject.otherCaco-2en_US
dc.subject.otherPermeabilityen_US
dc.subject.otherBiochemistry, Generalen_US
dc.subject.otherPharmacology/Toxicologyen_US
dc.subject.otherPharmacyen_US
dc.titleAbsorption Rate Limit Considerations for Oral Phosphate Prodrugsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumCollege of Pharmacy, The University of Michigan, 428 Church Street, Ann Arbor, Michigan, 48109en_US
dc.contributor.affiliationumCollege of Pharmacy, The University of Michigan, 428 Church Street, Ann Arbor, Michigan, 48109en_US
dc.contributor.affiliationumCollege of Pharmacy, The University of Michigan, 428 Church Street, Ann Arbor, Michigan, 48109en_US
dc.contributor.affiliationumCollege of Pharmacy, The University of Michigan, 428 Church Street, Ann Arbor, Michigan, 48109en_US
dc.contributor.affiliationotherAventis Pharmaceuticals, 1041 Route 202-206 North, P.O. Box 6800, Bridgewater, New Jersey, 08807en_US
dc.contributor.affiliationotherDepartment of Pharmaceutical Chemistry, University of Kuopio, P.O. Box 1627, FIN-70211, Kuopio, Finlanden_US
dc.contributor.affiliationotherPharmaceutical Research Laboratory, Taiho Pharmaceutical Co., Ltd., Kowauchi-cho, Tokushima, 771-01, Japanen_US
dc.contributor.affiliationotherDepartment of Pharmacology and Toxicology, University of Kuopio, P.O. Box 1627, FIN-70211, Kuopio, Finlanden_US
dc.contributor.affiliationotherDepartment of Pharmaceutical Chemistry, University of Kuopio, P.O. Box 1627, FIN-70211, Kuopio, Finlanden_US
dc.contributor.affiliationumcampusAnn Arboren_US
dc.identifier.pmid12817887en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/41498/1/11095_2004_Article_465513.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1023/A:1023827017224en_US
dc.identifier.sourcePharmaceutical Researchen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.